AbbVie (ABBV) Tops Q3 EPS by 8c, Offers Guidance

AbbVie (NYSE: ABBV) reported Q3 EPS of $3.82, $0.08 better than the analyst estimate of $3.74. Revenue for the quarter came in at $17.4 billion versus the consensus estimate of $17.36 billion.

GUIDANCE:

AbbVie sees FY2026 EPS of $13.95-$13.99, versus the consensus of $13.95.

AbbVie is raising its adjusted diluted EPS guidance for the full year 2026 from $13.76 - $13.96 to $13.95 - $13.99, which includes an unfavorable impact of $0.69 per share related to acquired IPR&D and milestones expense incurred year-to-date through the third quarter 2026. The company's 2026 adjusted diluted EPS guidance excludes any impact from acquired IPR&D and milestones that may be incurred beyond the third quarter of 2026, as both cannot be reliably forecasted.

For earnings history and earnings-related data on AbbVie (ABBV) click here.

You May Also Be Interested In

• Goldman Sachs Updates US Conviction List Directors' Cut
• Evercose ISI downgrades Reddit, says monetization may not offset traffic weakness
• AbbVie beats estimates but stock dips